<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303017</url>
  </required_header>
  <id_info>
    <org_study_id>Primus Protocol #OAPS</org_study_id>
    <nct_id>NCT00303017</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study</brief_title>
  <official_title>Safety, Efficacy and Acceptability of Flavocoxid (Limbrel) Compared With Naproxen in Subjects With Osteoarthritis of the Knee. A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Primus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Primus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      safety, efficacy and acceptability of Flavocoxid
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety, Efficacy and acceptability of Flavocoxid (Limbrel) compared with Naproxen in Subjects
      with Osteoarthritis of the Knee. A Pilot Study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate safety</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>flavocoxid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medical food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NSAID</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flavocoxid</intervention_name>
    <description>flavonoid mixture</description>
    <arm_group_label>flavocoxid</arm_group_label>
    <other_name>Limbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>non-steroidal anti-inflammatory drug</description>
    <arm_group_label>naproxen</arm_group_label>
    <other_name>naprosyn</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        OA of the knee,K-L grade 2-3 in general good health is currently taking an NSAID or COX-2
        inhibitor -

        Exclusion Criteria:

        pregant or nursing women grade 1 or 4 OA any significant medical condition that in the
        opinion of the physician might put the subject at risk in this study any form of
        arthropathy other than OA any condition that might confound the evaluation of the pain,
        stiffness or function of the target joint intra-articular cotticosteroid inkection in the
        target joint within 3 month of the screening visit concomitant use of other
        anti-inflammatory or anti arthritic medication or products(including OTC and herbal
        preparations) Low dose aspirin for cardio-protection is allowed concomitant use of coumadin
        or other anticoagulant or anti-platelet medication concomitant use of gastro-protectiv
        medications including, but not limited to, H2 blockers and proton pump inhibitors,
        including OTC and herbal products History of allergy to Flavonoids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy Schechtman, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Valley Arthritis Ltd, 6525 W. Sack Drive Suite 108 Glendale AZ 85308 Phone 623-825-5591 Fax 623</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Truitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MIMA Century Research Associates 65 E. Nasa Blvd. Suite 106 Melbourne FL 32901 Phone 321 723-1203 Fax 321-725-3602</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Timothy Truitt MD</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.primusrx.com</url>
    <description>Primus Pharmaceuticals, Inc</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2006</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

